Other OTC - Delayed Quote USD

Smith & Nephew plc (SNNUF)

12.81 0.00 (0.00%)
As of May 10 at 11:43 AM EDT. Market Open.
Loading Chart for SNNUF
DELL
  • Previous Close 12.81
  • Open 12.55
  • Bid --
  • Ask --
  • Day's Range 12.81 - 12.81
  • 52 Week Range 10.80 - 16.10
  • Volume 1
  • Avg. Volume 1,870
  • Market Cap (intraday) 11.2B
  • Beta (5Y Monthly) 0.51
  • PE Ratio (TTM) 42.70
  • EPS (TTM) 0.30
  • Earnings Date Aug 1, 2024
  • Forward Dividend & Yield 0.38 (2.93%)
  • Ex-Dividend Date Mar 28, 2024
  • 1y Target Est --

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products. It also provides sports medicine joint repair products comprise instruments, technologies, and implants to perform minimally invasive surgery, as well as treating soft tissue injuries and degenerative conditions of the shoulder, knee, hip, and small joints. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high-definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg wounds, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, such as biologics and other bioactive technologies for debridement and dermal repair/regeneration, and regenerative medicine products, including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. The company serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.

www.smith-nephew.com

18,452

Full Time Employees

December 31

Fiscal Year Ends

Recent News: SNNUF

Performance Overview: SNNUF

Trailing total returns as of 5/15/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

SNNUF
5.86%
FTSE 100
9.21%

1-Year Return

SNNUF
14.78%
FTSE 100
8.91%

3-Year Return

SNNUF
34.71%
FTSE 100
19.91%

5-Year Return

SNNUF
29.07%
FTSE 100
16.63%

Compare To: SNNUF

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: SNNUF

Valuation Measures

Annual
As of 5/14/2024
  • Market Cap

    11.18B

  • Enterprise Value

    13.96B

  • Trailing P/E

    42.56

  • Forward P/E

    13.02

  • PEG Ratio (5yr expected)

    0.48

  • Price/Sales (ttm)

    2.02

  • Price/Book (mrq)

    2.15

  • Enterprise Value/Revenue

    2.52

  • Enterprise Value/EBITDA

    14.60

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    4.74%

  • Return on Assets (ttm)

    4.27%

  • Return on Equity (ttm)

    5.02%

  • Revenue (ttm)

    5.55B

  • Net Income Avi to Common (ttm)

    263M

  • Diluted EPS (ttm)

    0.30

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    302M

  • Total Debt/Equity (mrq)

    59.11%

  • Levered Free Cash Flow (ttm)

    211.75M

Research Analysis: SNNUF

Company Insights: SNNUF

Research Reports: SNNUF

People Also Watch